Healthcare
CG Oncology, Inc.(CGON)
Live Price
Offline$59.56
+3.33% today
1Y Change
+163.70%
Window
Jun 25, 2025 β Jun 24, 2026
- Market Cap
- $5.67B
- Revenue Growth
- +254.7%
- EPS Growth
- -47.5%
- Dividend Yield
- 0.0%
Coverage: 250 bars Β· Jun 25, 2025 β Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CG Oncology, Inc. (CGON) is a Healthcare stock with a market cap of $5.67B and listed on NASDAQ. The stock last traded around $59.56 and up 163.7% across the available one-year price window (Jun 25, 2025 β Jun 24, 2026). Baseline metrics include revenue growth of +254.7%, EPS growth of -47.5%, a dividend yield of 0.0%. What stands out right now is revenue +254.7%, EPS -47.5%, free cash flow -67.8% with operating margin -4722.1% and ROIC -25.0%. Valuation already assumes a fairly strong business story at price/sales 1403.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CGON price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+254.7% vs +7.6% peer median
Operating Margin
Below sector median
-4722.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +254.7% and EPS is at -47.5%, with operating margin around -4722.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | β | +0.6% | +0.5% | -22.3% |
2026 Feb 27, 2026 | +16.4% | -1.8% | +5.2% | +9.9% |
2025 Nov 14, 2025 | -2.0% | +0.6% | +3.5% | -3.1% |
Benchmark Edge
CGON vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CGON
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CGON Max Drawdown
-27.41%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CGON and SPY.
Company Overview
CG Oncology, Inc.
NASDAQ
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy currently advancing through two Phase 3 clinical trialsβBOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBCβas well as the Phase 2 CORE-008 study combining it with a checkpoint inhibitor for high-risk BCG-unresponsive disease. The company targets urologic cancers, addressing significant unmet needs in BCG-unresponsive and intermediate-risk settings where durable, bladder-preserving options are limited. Headquartered in Irvine, California, CG Oncology engages in clinical development, regulatory interactions including a rolling Biologics License Application submission and Fast Track designation, and supports research through programs like fellowships at urologic conferences. This positions CG Oncology as a key player in oncology biotechnology, emphasizing innovative intravesical therapies to improve patient outcomes in bladder cancer treatment.
- Leadership
- Mr. Arthur Kuan
- Employees
- 142
- Street Address
- 400 Spectrum Center Drive, Suite 2040
- Mailing
- Irvine, CA, 92618
- Region
- Irvine, CA, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 1403.9
- Price/Book
- 6.9
Growth
- Revenue
- +254.7%
- EPS
- -47.5%
- Free Cash Flow
- -67.8%
Profitability
- Gross Margin
- -15.0%
- Operating Margin
- -4722.1%
- Net Margin
- -3985.0%
- ROE
- -22.9%
- ROIC
- -25.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 24.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.